In the current study, we found synergistic cytotoxic effects in FLT3 wild-type AML cell lines treated with combinations of the STAT5 inhibitor AC-4-130 and the MCL1 inhibitor S63845, and in the FLT3-ITD-positive MOLM-13 cells treated with combinations of the STAT5 inhibitor AC-4-130 and the FLT3 inhibitor midostaurin (PKC412). Here, MCL1 is linked to acute myeloid leukemia.